DNLI Denali Therapeutics Inc.
$19.22▲ +3.00%
Healthcare
Other
After hours
$19.22▲ +0.00%
Oct 27, 4:01 PM ET
Volume 1.48M
Avg Volume (10D) 1.70M
Key Metrics & Fundamentals
Market Cap
$3.07B
P/E Ratio
–
Div Yield
0.00%
52W Range
13.75 - 27.30
% vs 50 MA
-8.43%
% vs 200 MA
-9.42%
RSI-14
47.9
MACD Histogram
+0.1700
Beta (1Y vs SPY)
1.53
Free Cash Flow
-$126.61M
Gross Rev
$3.60M
Gross Profit
$3.51M
EBITDA
-$126.06M
COGS
$93,000
Operating Exp
$134.05M
Operating Income
-$130.54M
EBIT
-$130.54M
Pretax Income
-$127.55M
Net Income
-$127.55M
EPS (Diluted)
-0.68
Price & Volume History
Loading chart…
Recent News
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
GlobeNewswire · Oct 22, 2026 4:01 PM ET
Wedbush Cuts Price Target on Denali Therapeutics to $23 From $27, Keeps Outperform Rating
MT Newswires · Oct 19, 2026 7:14 AM ET
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Zacks · Oct 14, 2026 9:30 AM ET
Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
PR Newswire · Oct 13, 2026 10:31 AM ET
Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?
Simply Wall St. · Oct 9, 2026 11:22 PM ET
Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?
Simply Wall St. · Oct 9, 2026 3:15 AM ET
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing
MT Newswires · Sep 4, 2026 5:12 PM ET
B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating
MT Newswires · Aug 25, 2026 7:55 AM ET
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Zacks · Aug 20, 2026 12:20 PM ET
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Zacks · Aug 20, 2026 10:12 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See DNLI's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.